Adverse effects and other safety aspects of the hepatitis C antivirals.

@article{Chutaputti2000AdverseEA,
  title={Adverse effects and other safety aspects of the hepatitis C antivirals.},
  author={Anuchit Chutaputti},
  journal={Journal of gastroenterology and hepatology},
  year={2000},
  volume={15 Suppl},
  pages={E156-63}
}
The preferred treatment for patients with chronic hepatitis C, either treatment-naive, relapsers or nonresponders to IFN monotherapy, is now IFN-ribavirin combination treatment. The adverse effects of IFN are well established and familiar to hepatologists all over the world. More than 25,000 patients worldwide have been treated with combination therapy. Patients re-treated with a combination regimen are more likely to tolerate IFN better than treatment-naive patients, probably due to better… CONTINUE READING